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Abstract
We report a dystrophinopathy patient with an in-frame deletion of DMD exons
45–47, and therefore a genetic diagnosis of Becker muscular dystrophy, who
presented with a more severe than expected phenotype. Analysis of the patient
DMD mRNA revealed an 82 bp pseudoexon, derived from intron 44, that dis-
rupts the reading frame and is expected to yield a nonfunctional dystrophin.
Since the sequence of the pseudoexon and canonical splice sites does not differ
from the reference sequence, we concluded that the genomic rearrangement
promoted recognition of the pseudoexon, causing a severe dystrophic pheno-
type. We characterized the deletion breakpoints and identified motifs that
might influence selection of the pseudoexon. We concluded that the donor
splice site was strengthened by juxtaposition of intron 47, and loss of intron 44
silencer elements, normally located downstream of the pseudoexon donor splice
site, further enhanced pseudoexon selection and inclusion in the DMD tran-
script in this patient.
Introduction
The most common mutations in the dystrophin (DMD)
gene are deletions of one or more exons (Den Dunnen
et al. 1989) and those that disrupt the open reading frame
and ablate or dramatically reduce muscle dystrophin
cause the fatal disease, Duchenne muscular dystrophy
(DMD) (MIM #310200). In-frame deletions do not dis-
rupt the reading frame and generally yield a shortened
dystrophin of variable quality and function (Monaco
et al. 1988). In these cases, patients typically present with
the milder condition, Becker muscular dystrophy (BMD)
(MIM #300376), and remain ambulant beyond 15 years
of age, whereas DMD patients lose the ability to walk by
age 12. One of the more common in-frame deletions
expected to cause a BMD phenotype is that of exons
45–47 (Bushby et al. 1993).
In this study we report on a patient, identified as hav-
ing a deletion of exons 45–47 and therefore a genetic
diagnosis of BMD, who presented with an intermediate/
severe BMD clinical phenotype and lost ambulation by
the age of 15 years. Analysis of the DMD mRNA from
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the patient described here revealed that a pseudoexon of
82 nucleotides, derived from intron 44, (pseudoexon 44a)
was included in the DMD transcript disrupting the open
reading frame to yield a truncated, nonfunctional dystro-
phin. Since the sequence of the pseudoexon and flanking
canonical splice sites are identical to the reference
sequence, we concluded that the genomic deletion
brought together elements promoting recognition and
selection of exon 44a into the mature mRNA, causing a
more severe dystrophic phenotype than would be
expected from the loss of exons 45–47.
We sought to fully characterize the mutation in this
patient, by mapping the deletion breakpoints and sequenc-
ing of the pseudoexon 44a and flanking regions, in order
to identify motifs that might influence selection of the
pseudoexon by the splicing machinery. We concluded that
the pseudoexon donor splice site was strengthened by the
close proximity of motifs from intron 47, and that the loss
of intron 44 silencer elements normally downstream of the
pseudoexon donor splice site further enhanced exon selec-
tion and inclusion in the DMD transcript.
The patient was reported with a deletion of dystrophin
exons 45–47 (NG_012232.1(DMD):c.6439-?_6912+?del)
but presented with a severe BMD/intermediate (IMD)
phenotype. Dermal fibroblasts were prepared from a skin
biopsy and provided by MRC Centre for Neuromuscular
Diseases, Institute of Genetic Medicine, Newcastle Univer-
sity, Newcastle-Upon-Tyne, U.K. The study received
approval from the Human Ethics Committee at Murdoch
University (approval number 2013/156) and The Univer-
sity of Newcastle University (approval number 08/H0906/
28+5). Fibroblasts were also derived from a small biopsy
donated by a normal individual, with informed consent.
Fibroblasts were propagated in Dulbecco’s modified Eagle
medium (DMEM) (Life Technologies, Melbourne, Austra-
lia) supplemented with 15% fetal bovine serum (Serana,
Bunbury, Australia) and induced into the myogenic line-
age with a MyoD-expressing adenovirus, Ad5.f50.AdApt.-
MyoD (Native Antigen Company, Oxford, U.K.)
(Lattanzi et al. 1998), at an MOI of 200 and allowed to
differentiate as described previously (Fletcher et al. 2013).
Total RNA was extracted from cultured cells and used as
template (50 ng) in an RT-PCR amplifying across exons
43–51 (Wilton et al. 2007; Fletcher et al. 2013). This assay
allows detection of various RNA processing events,
including cryptic splice site activation or endogenous
exon skipping in the region of the deletion.
The patient sample yielded a major product of 835 bp
as well as an occasional minor product of approximate
size 750 bp (Fig. 1A), and the full-length product ampli-
fied from the normal RNA is of the expected size
(1227 bp). It was expected that a patient with a DMD
deletion of exons 45–47 would yield an amplicon of
753 bp, apparent as a very minor product in both patient
and normal samples. Sporadic alternative splicing of the
DMD transcript and generation of revertant transcripts
has been widely reported, and transcripts missing a num-
ber of exons, including exons 45–47 are frequently
observed in both normal and DMD muscle. Sequencing
of the larger patient amplicon revealed the inclusion of a
pseudoexon (exon 44a) of 82 bp derived from DMD
intron 44 (NG_012232.1(DMD):c.6438_6439ins6438+
192432_6438+192514) or (NG_012232.1(DMD):c.[6439-
55886_6913-27860del;6438_6439ins6439-55969_6439-55888].
The sequence of exon 44a was unchanged relative to the
reference sequence (NG_012232.1) that includes putative
canonical acceptor and donor sites (Fig. 1B–D), with
splice scores of 85.36 and 71.09, respectively using the
Analyzer Splice Tool (http://ibis.tau.ac.il/ssat/SpliceSite-
Frame.htm) (Table 1). We confirmed that the intron 44
sequence upstream of the pseudoexon location was also
unchanged, and we then proceeded to locate the junction
of introns 44 and 47.
DNA was extracted from cultured fibroblasts, using the
DNeasy Blood & Tissue kit (Qiagen, Melbourne, Austra-
lia) and used as the template in PCRs examining the
DMD mutation and deletion breakpoints. Primer sets
were designed to amplify discrete ~350–700 bp products
at ~7 kb intervals in intron 44, downstream of the
pseudoexon and at ~5 kb intervals in intron 47 (Fig. 2A)
and used to amplify DNA from both the patient and a
normal individual. Amplicons of the expected size were
generated from both patient and normal control DNA by
primer sets 12–16, whereas sets 1–11 yielded amplicons
from only the normal DNA, suggesting that the break-
point lay within intron 47, very close to the donor site of
the pseudoexon (Fig. 2B).
In order to precisely locate the breakpoint, primers
spanning the pseudoexon and the closest known sequence
within intron 47 of the patient DMD gene were used to
amplify patient DNA and each of the PCRs yielded a sin-
gle amplicon (data not shown). Sequencing of the ampli-
cons revealed that the junction of introns 44 and 47 in
the patient lay one (or two) bases downstream of the
cryptic donor splice site of the pseudoexon that adjoins
~26 kb into intron 47 (Fig. 2C). The juxtaposition of
intron 47 and the pseudoexon at this point strengthens
the donor splice site from 71.09 to 84.57 (Table 1). The
reference sequence shows a “t” at location +2 relative to
the pseudoexon donor splice site in both intron 44 and
intron 47 at this location (Fig. 2D), so the origin of
the base remains ambiguous (NG_012232.1(DMD_v001):
c.6439-55886_6912+26363del,6438_6439ins6439-55969_
6439-55888) or (NG_012232.1(DMD):c.[6439-55886_6913-
27860del;6438_6439ins6439-55969_6439-55888]. Analysis
of the DMD intron 44 region revealed a number of pre-
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dicted splicing motifs (Desmet et al. 2009) present in the
normal intron 44 sequence, including the location of exon
44a and downstream bases. Figure 3 shows 4 exon
splicing silencer (ESS) motifs immediately downstream of
the donor splice site for 44a in the normal sequence that
are missing from the patient sequence.
Table 1. Potential donor splice site position, splicing motif and splice scores, as determined using the Analyzer Splice Tool (http://ibis.tau.ac.il/
ssat/SpliceSiteFrame.htm), within the cryptic pseudoexon 44a sequence in normal and patient DMD intron 44.
Sequence position cDNA position Splice site type Motif New potential splice site Consensus value (0–100)
(A) Normal intron 44 region around cryptic pseudoexon 44a
30 28 Donor GGAGTGAGG GGAgtgagg 79.71
35 33 Donor GAGGTGGCG GAGgtggcg 74.79
56 54 Donor ACTGTAACC ACTgtaacc 69.24
76 74 Donor CAGGTTCGA CAGgttcga 83.84
82 80 Donor CGAgtgatt CGAgtgatt 71.09
108 25 Donor gaagtacct GAAgtacct 66.84
124 41 Donor taggtgccc TAGgtgccc 73.87
(B) Patient intron 44 region around cryptic pseudoexon 44a
30 28 Donor GGAGTGAGG GGAgtgagg 79.71
35 33 Donor GAGGTGGCG GAGgtggcg 74.79
56 54 Donor ACTGTAACC ACTgtaacc 69.24
76 74 Donor CAGGTTCGA CAGgttcga 83.84
82 80 Donor CGAgtaagt CGAgtaagt 84.57
86 3 Donor taagtatga TAAgtatga 76.3
113 30 Donor ttggtactt TTGgtactt 72.15
135 52 Donor caggttgaa CAGgttgaa 72.14
141 58 Donor gaagtgaca GAAgtgaca 72.15
164 81 Donor taagttaaa TAAgttaaa 67.92
DMD, dystrophin gene.
A
B       C
835bp
(Δ 45-47 ins 44a )
Exon 44                        Exon 44a                               Exon 44a                            Exon 48
1227bp (Full length 43-51)
753bp   (Δ 45-47)
No
rma
l R
NA
Pa
tien
t R
NA
Lad
der
-ve
ATCTTAAGAGGGAGTTTCGCTCTTTCGCCCAGGCTGGAGTGAGGTGGCGCAATCTCAGCTGACTGTAACCTCTGCCCCCACCAGGTTCGAGTTTCCAG
148                82                                                                                         186 nucleotides
D
Exon 44                                          Exon 44a                                                                                Exon 48
Figure 1. Pseudoexon identification. (A) RT-PCR amplification of normal human and DMD exon 45–47 deletion patient RNA samples, across
dystrophin exons 43–51. Amplicon sizes are indicated, (expected size for the normal DMD transcript product is 1227 nucleotides, while DMD
deletion of exons 45–47 should generate a 753 nucleotide product (M = 100 bp size standard ladder). The predominant transcript product
amplified from patient RNA is 835 bp. Sequencing chromatograms showing the junctions of exon 44 (B) and 44a, and 44a and exon 48 (C). (D)
Sequence of the 82 bp pseudoexon (exon 44a-shaded) derived from intron 44, and inserted between exons 44 and 48. The exon junctions are
indicated by arrows and in-frame termination codons are shown in red. Exon sizes (bp) are indicated in italics. DMD, dystrophin gene.
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The patient participating in this study shows a clinical
phenotype that is not consistent with deletion of DMD
exons 45–47. He lost independent ambulation by age
15 years. His cardiac function revealed a left ventricular
(LV) shortening fraction of 32% and some evidence of
LV dilatation at 15 years of age, at which time he was
started on a beta-blocker. At 18½ years of age he had an
LV shortening fraction of 28%. The patient would be
considered to have an intermediate dystrophinopathy
phenotype, as he remained able to push himself in a
manual wheelchair at 18½ years of age. Given the nature
of his deletion, however, he would have been expected to
have a classical BMD clinical presentation.
Clinical variability resulting from in-frame deletions in
this region of the DMD gene has been widely reported. A
recent study of 13 patients reported that dystrophin levels
in this group varied from 13% to 76% of normal levels
but did not correlate with function provided that dystro-
phin levels were above ~10% of normal levels (van den
Bergen et al. 2014). Similar data for in-frame deletions in
this region of the DMD gene have been reported in earlier
studies. Three patients missing DMD exons 45–47 had
only 5% of normal muscle dystrophin levels and mani-
fested moderate/severe dystrophy, while the other seven
patients in the study, with variable mild to moderate
symptoms had 20–80% of the dystrophin level found in
normal healthy muscle (Kesari et al. 2008). Eleven of 43
BMD/IMD patients showed deletion of exons 45–47, with
muscle dystrophin levels averaging 44% of normal (Beggs
et al. 1991). Most had fairly slow progression, with four
patients ranging in age from 28 to 42 remaining ambulant.
However, two patients in this group were atypical, one
had severe difficulty climbing stairs and the other had
gross motor deficits at age 4 years and would therefore be
regarded as IMD/DMD. Winnard et al. (1993) also
reported a DMD 45–47 deletion patient as intermediate,
while Dastur et al. (2008) described two of 16 patients
with deletion of exons 45–47 as DMD, the remaining 14
patients are documented as BMD.
Although precise explanations for the more severe
manifestation in some patients, expected to have BMD on
the basis of in-frame genomic deletions, have not been
reported, Muntoni and colleagues speculated that differ-
ences in the deletion breakpoints within introns could be
a contributory factor (Muntoni et al. 2003). They con-
cluded that patients with apparently identical exonic dele-
tions are almost certainly going to have different genomic
breakpoints and therefore will be missing different intronic
regions, and potentially, splicing motifs. Such insight,
together with the accumulating evidence of poor geno-
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Figure 2. Localization of intronic breakpoints in the DMD exon 45–47 deletion patient. (A) Cartoon showing postulated structure of the patient
dystrophin gene between pseudoexon 44a and exon 48. (B) Amplification of patient and normal DNA using primer sets designed to amplify
discrete ~350–700 bp products within DMD introns 44, downstream of the pseudoexon 44a (primer sets 1–6) and 47 (primer sets 7–16
[N = normal individual, P = DMD exon 45–47 deletion patient]). (C) Pseudoexon 44a (shaded, uppercase) and flanking intronic sequence
(lowercase) showing canonical splice sites (bold, underlined). (D) Sequencing chromatogram showing the location of pseudoexon 44a (shaded)
and the intron 44 (blue box) and 47 (red box) breakpoints. The origin of the “T”, two bases downstream of the 44a donor splice site remains
ambiguous and is indicated by the cyan double headed arrow. DMD, dystrophin gene.
323ª 2015 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
K. Greer et al. Dystrophin Pseudoexon Activation in Severe BMD
type–phenotype correlation for some patients with in-
frame deletions demands more careful consideration of
the nature of DMD genomic rearrangements.
Pseudoexon activation by altered intronic arrangements
is not unprecedented. A rare intra-intronic deletion
resulted in the incorporation of a segment of intron 11 as
a cryptic exon into the DMD transcript, rendering the
transcript out of frame. The aberrant transcript coexisted
with a normal product in skeletal muscle, but was the
only DMD mRNA in cardiac muscle (Ferlini et al. 1998).
Individual differences in transacting splicing factors are
likely to play a role in exon selection and differential
dystrophin expression (Sironi et al. 2003) and deletions
involving the same exons can determine diverse splicing
behaviors in different patients or in different tissues of
the same individual (Sironi et al. 2002).
There is currently no cure for DMD or BMD and until
recently, these conditions have been managed by support-
ive therapies and administration of steroids (Bushby et al.
2010; Guglieri and Bushby 2010; Rodino-Klapac et al.
2013). Such therapies are beneficial for quality of life and
managing comorbidities, but do not address the primary
cause of the disease nor alter disease progression. Recent
advances have given rise to promising potential therapies
Figure 3. Predicted splicing motifs for the
dystrophin gene pseudoexon 44a region in
normal and patient DNA. (A) Predicted splicing
motifs in normal intron 44 sequence including
the location of 44a and downstream bases
(Desmet et al. 2009). Asterisk denotes four
exon splicing silencer (ESS) motifs immediately
downstream of the donor splice site for 44a.
(B) Predicted splicing motifs in the patient
pseudoexon 44a region including downstream
intron 47 bases.
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for DMD and have shown that molecular strategies can
restore dystrophin in DMD muscle (Malik et al. 2010;
Cirak et al. 2011; Mendell et al. 2013), for review see
(Wilton and Fletcher 2011). Those that are mutation spe-
cific, such as premature termination codon read-through
compounds and splice switching antisense oligomers
(AOs), demand precise mutation characterization, and
analysis of dystrophin expression.
AOs are single-stranded nucleic acid analogs that can
be used to alter exon selection in order to restore the
reading frame around a gene lesion or remove exons car-
rying nonsense mutations, and are showing promise in
DMD (for review see Wilton and Fletcher 2011; Arechav-
ala-Gomeza et al. 2012). The internally truncated dystro-
phin isoforms encoded by the manipulated transcripts
contain the necessary N- and C-terminal domains that
allow interaction with cytoskeletal actin and the dystro-
phin-associated protein complex (for review see Cohn
and Campbell 2000). The production of even low levels
of these BMD-like dystrophin isoforms is postulated to
allow partial restoration of the dystrophin-associated pro-
tein complex, decreasing the rate of muscle fiber degener-
ation and conferring a degree of clinical benefit in DMD
patients (Mendell et al. 2013).
To date, patients deemed to be “BMD”, on the basis of
having in-frame deletions, have not been considered as
candidates for exon skipping therapies. However, we sug-
gest that reframing the dystrophin transcript in this
patient by AO-mediated skipping of pseudoexon 44a
could be expected to generate a functional dystrophin iso-
form and stabilize the dystrophic phenotype. Most
patients with deletions of exons 45–47 show a mild BMD
phenotype, and the minority of these patients reported to
have a more severe presentation may also have more
complex rearrangements or splice aberrations.
Our findings have important implications for clinical
studies that aim to restore dystrophin expression in DMD
patients with frame-shift deletions in this region. Rare
splicing anomalies might be implicated in other geno-
type–phenotype inconsistencies, emphasizing the need to
analyze the patient transcript in such cases. Discrepancies
between genotype and phenotype should not be cited in
order to undermine the predicted functionality of “BMD-
like” dystrophin variants when designing exon skipping
strategies to treat DMD. Such anomalous cases do not
accurately reflect the clinical range for the selected patient
group, if an individual’s clinical status is compromised by
aberrant splicing events.
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